Printed from https://ideas.repec.org/s/spr/eujhec9.html
Content
August 2008, Volume 9, Issue 3
- 261-264 Choice determinants of the mobility in the Dutch health insurance market
by Ilaria Mosca & Anoushka Schut-Welkzijn - 265-274 Predisposing factors for early retirement in patients with Schizophrenia in Germany
by Reinhard Schnabel & Heiko Friedel & Andreas Erfurth & Matthias Angermayer & Johannes Clouth & Florian Eichmann - 275-284 Preferences and utilities for the symptoms of moderate to severe allergic asthma
by Andrew Lloyd & Scott Doyle & Sarah Dewilde & Florian Turk - 285-292 In pursuit of QALY weights for relatives: empirical estimates in relatives caring for older people
by Thomas Davidson & Barbro Krevers & Lars-Åke Levin - 293-304 A theoretical and empirical investigation of nutritional label use
by Andreas Drichoutis & Panagiotis Lazaridis & Rodolfo Nayga & Maria Kapsokefalou & George Chryssochoidis - 305-310 Pricing and reimbursement of pharmaceuticals in Italy
by Pietro Folino-Gallo & Simona Montilla & Mario Bruzzone & Nello Martini
May 2008, Volume 9, Issue 2
- 99-101 The CHESME Health Economic Evaluations Database (CHESME HEED) project
by Dimitrios Rovithis & Lycurgus Liaropoulos - 103-115 Costing maternal health services in South Tanzania
by Claudia Both & Albrecht Jahn & Steffen Fleßa - 117-125 Primary physicians’ response to changes in fees
by Jostein Grytten & Fredrik Carlsen & Irene Skau - 127-136 The search for good compliance: economic aspects of a conveyed combination pharmaco-therapy, exemplified by an osteoporosis therapy
by Peter Oberender & Jürgen Zerth - 137-145 Methodological issues in undertaking independent cost-effectiveness analysis for NICE: the case of therapies for ADHD
by Susan Griffin & Helen Weatherly & Gerry Richardson & Mike Drummond - 147-156 The role of non-need factors in individual GP utilisation analysis and their implications for the pursuance of equity: a cross-country comparison
by P. McGregor & P. McKee & C. O’Neill - 157-163 Eligibility for free GP care, “need” and GP visiting in Ireland
by A. Nolan & B. Nolan - 165-170 Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial
by Hans Janka & Barbara Högy - 171-183 Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective
by Jonathan Karnon & Thomas Delea & Vicki Barghout - 185-191 The impact of generic substitution on price competition in Finland
by Ville Aalto-Setälä - 193-201 Spillover of cause-specific longevity interventions: an independent mortality risk model
by Liqun Liu - 203-203 Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance
by Barbara Högy & Heinz-Otto Keinecke & Michael Borte
November 2008, Volume 9, Issue 1
- 1-3 Evidence-based benefit assessment of pharmaceuticals as a basis for rational and economical pharmaceutical therapy
by Thomas Müller - 5-29 Procedures and methods of benefit assessments for medicines in Germany
by Geertruida Bekkering & Jos Kleijnen - 31-43 Biostatistical aspects for the use of evidence based medicine in health technology assessment
by Nick Freemantle
February 2008, Volume 9, Issue 1
- 1-6 Alcohol consumption in the EU: health economics and policy issues under a permanent debate
by Fernando Antoñanzas & Roberto Rodríguez-Ibeas & Emilio Barco & Manuel Ramírez & Mariola Pinillos - 7-15 Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects
by Adam Lloyd & Nishma Patel & David Scott & Claus Runge & Christa Claes & Markus Rose - 17-22 Estimation and comparison of ostomy appliance costs with tariffs in Belgium
by Veerle Vanleene & Luc Maré & Ingrid Moldenaers & Hans Debruyne & Steven Simoens & Dirk Steen & Dirk Ramaekers - 23-32 Influence of bacterial resistances on the efficiency of antibiotic treatments for community-acquired pneumonia
by Ramon Sabes-Figuera & José Segú & Jaume Puig-Junoy & Antoni Torres - 33-39 Vaccination versus “wait and treat”: how to subsidize them?
by Louis Eeckhoudt & Maurice Marchand & Pierre Pestieau & Gwenaël Piaser - 41-50 The differences in characteristics between health-care users and non-users: implication for introducing community-based health insurance in Burkina Faso
by Hengjin Dong & Adjima Gbangou & Manuela Allegri & Subhash Pokhrel & Rainer Sauerborn - 51-61 Work environment satisfaction and employee health: panel evidence from Denmark, France and Spain, 1994–2001
by Nabanita Datta Gupta & Nicolai Kristensen - 63-67 Does greater exposure to own-health data make a difference on the visual analog scale?
by Amir Shmueli & David Messika & Havi Murad & Laurence Freedman - 69-78 Willingness to pay for a reduction in mortality risk after a myocardial infarction: an application of the contingent valuation method to the case of eplerenone
by Jose-Luis Pinto-Prades & Veronica Farreras & Jaime de Bobadilla - 79-86 Factors influencing hospital costs of lung cancer patients in Northern Ireland
by Ian Fleming & Pauline Monaghan & Anna Gavin & Ciaran O’Neill - 87-97 Pharmaceutical pricing and reimbursement reforms in Greece
by John Yfantopoulos
January 2008, Volume 8, Issue 2
- 33-34 Patient access to rheumatoid arthritis treatments
by Bengt Jönsson & Gisela Kobelt & Josef Smolen - 35-38 Patient access to rheumatoid arthritis treatments
by Bengt Jönsson - 39-47 The burden of rheumatoid arthritis and access to treatment: a medical overview
by J. Smolen & D. Aletaha - 49-60 The burden of rheumatoid arthritis and access to treatment: health burden and costs
by J. Lundkvist & F. Kastäng & G. Kobelt - 61-86 The burden of rheumatoid arthritis and access to treatment: uptake of new therapies
by B. Jönsson & G. Kobelt & J. Smolen - 87-93 The burden of rheumatoid arthritis and access to treatment: determinants of access
by J. Lundqvist & F. Kastäng & G. Kobelt & B. Jönsson - 95-106 The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments
by G. Kobelt & B. Jönsson
December 2007, Volume 8, Issue 4
- 301-304 Tobacco policies in the European Union: a need for state and continental harmonisation?
by Fernando Antoñanzas & Roberto Rodríguez - 305-312 Foreign direct investment in the health care sector and most-favoured locations in developing countries
by J. Outreville - 313-323 Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery
by Jonas Lundkvist & David Bergqvist & Bengt Jönsson - 325-332 The impact of home hospitalization on healthcare costs of exacerbations in COPD patients
by Jaume Puig-Junoy & Alejandro Casas & Jaume Font-Planells & Joan Escarrabill & Carme Hernández & Jordi Alonso & Eva Farrero & Gemma Vilagut & Josep Roca - 333-337 Pricing matrix model: dealing with uncertainty
by Mark Nuijten - 339-346 The incidence and cost of cardiac surgery adverse events in Australian (Victorian) hospitals 2003–2004
by Jonathon Ehsani & Stephen Duckett & Terri Jackson - 347-357 Assessment of the pharmaceutical market in Poland after accession to the European Union
by Patricia Willert - 359-359 Costs and quality of life in multiple sclerosis in The Netherlands
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Bert Anten & Mattias Ekman & Peter Jongen & Chris Polman & Bernard Uitdehaag
September 2007, Volume 8, Issue 3
- 179-179 Editor’s note
by J.-Matthias Graf von der Schulenburg & Wolfgang Greiner - 181-193 Innovation in hospitals: a survey of the literature
by Faridah Djellal & Faïz Gallouj - 195-212 Risk adjustment policy options for casemix funding: international lessons in financing reform
by Kathryn Antioch & Randall Ellis & Steve Gillett & Daniel Borovnicar & Ric Marshall - 213-223 Incorporating efficiency in hospital-capacity planning in Germany
by Ludwig Kuntz & Stefan Scholtes & Antonio Vera - 225-236 Variations in activity and practice patterns: a French study for GPs
by Sophie Béjean & Christine Peyron & Renaud Urbinelli - 237-243 Income-related health inequality in Belgium: a longitudinal perspective
by Ann Lecluyse - 245-251 Economic impact of shifting the locus of care for neuropathic pain from specialists to general practitioners
by Ariel Berger & Piotr Kramarz & Gry Kopperud & John Edelsberg & Gerry Oster - 253-266 Patient access to pharmaceuticals: an international comparison
by Joshua Cohen & Laura Faden & Susan Predaris & Brian Young - 267-277 Supplier-induced demand: re-examining identification and misspecification in cross-sectional analysis
by Stuart Peacock & Jeffrey Richardson - 279-285 Is there an association between economic performance and public satisfaction in health care?
by Eddy Adang & George Borm - 287-295 Why do patients bypass the nearest hospital? An empirical analysis for orthopaedic care and neurosurgery in the Netherlands
by Marco Varkevisser & Stéphanie Geest - 297-300 Economic aspects of the new Spanish laws on pharmaceutical preparations
by Fernando Antoñanzas & Juan Oliva & Mariola Pinillos & Carmelo Juàrez
June 2007, Volume 8, Issue 2
- 83-88 The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience
by László Gulácsi - 89-95 Pharmacoeconomic studies in Italy: a critical review of the literature
by D. Cornago & L. Li Bassi & P. Compadri & L. Garattini - 97-103 The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management
by Vesna Bjegovic & Zorica Terzic & Jelena Marinkovic & Nebojsa Lalic & Sandra Sipetic & Ulrich Laaser - 105-110 Patients’ willingness to pay for electronic communication with their general practitioner
by Trine Bergmo & Silje Wangberg - 111-121 Systematic review of economic evaluations and cost analyses of guideline implementation strategies
by Luke Vale & Ruth Thomas & Graeme MacLennan & Jeremy Grimshaw - 123-135 Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain
by Maureen Rutten-van Mölken & Jan Oostenbrink & Marc Miravitlles & Brigitta Monz - 137-144 The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30–49
by Richard Norman & D. Evans & Douglas Easton & Kenneth Young - 145-151 Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system
by K. Le Lay & E. Myon & S. Hill & L. Riou-Franca & D. Scott & M. Sidhu & D. Dunlop & R. Launois - 153-160 An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany
by Sara Sheriff & K. Petry & Hans Ikenberg & Geoffrey Crouse & Peter Mazonson & Christopher Santas - 161-168 Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis
by Andrew Palmer & William Valentine & Joshua Ray & Stephane Roze & Noemi Muszbek - 169-170 Comment on: Should we really worry about “launch delays” of new drugs in OECD countries? by L. Garatinni and S. Ghislandi
by Joshua Cohen - 171-171 Should we really worry about “launch delays” of new drugs in OECD countries? Reply to J Cohen
by Livio Garattini - 173-177 Discussion point: should governments buy drug patents?
by Juan Llano
March 2007, Volume 8, Issue 1
- 1-3 Should we really worry about “launch delays” of new drugs in OECD countries?
by Livio Garattini & Simone Ghislandi - 5-15 Cost of breast cancer in Sweden in 2002
by Mathias Lidgren & Nils Wilking & Bengt Jönsson - 17-24 Better primary physician services lead to fewer hospital admissions
by Fredrik Carlsen & Jostein Grytten & Julie Kjelvik & Irene Skau - 25-30 Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy
by Peter Lindgren & Thomas Kahan & Neil Poulter & Martin Buxton & Patrick Svarvar & Björn Dahlöf & Bengt Jönsson - 31-39 Risk-adjusted capitation payments: how well do principal inpatient diagnosis-based models work in the German situation? Results from a large data set
by Corinne Behrend & Florian Buchner & Michael Happich & Rolf Holle & Peter Reitmeir & Jürgen Wasem - 41-50 Long-term absenteeism due to sickness in Sweden. How long does it take and what happens after?
by Daniela Andrén - 51-57 Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany
by B. Brüggenjürgen & P. Lindgren & B. Ehlken & H.-J. Rupprecht & S. Willich - 59-65 A multilevel analysis on the determinants of regional health care expenditure: a note
by Guillem López-Casasnovas & Marc Saez - 67-76 Resource use and costs associated with patients treated for depression in primary care
by P. Sobocki & M. Ekman & H. Ågren & I. Krakau & B. Runeson & B. Mårtensson & B. Jönsson - 77-82 A public–private analysis of the new Dutch health insurance system
by Hans Maarse & Yvette Bartholomée
September 2007, Volume 8, Issue 1
- 1-2 Economic evaluation for pharmaceuticals in Germany
by Bengt Jönsson - 3-3 Technology assessment in the German context
by Michael Drummond - 5-31 Methods for determining cost-benefit ratios for pharmaceuticals in Germany
by J.- Graf v. d. Schulenburg & Christoph Vauth & Thomas Mittendorf & Wolfgang Greiner
December 2006, Volume 7, Issue 4
- 223-224 Time for a common standard for cost-effectiveness in Europe?
by Bengt Jönsson - 225-230 Optional deductibles in social health insurance systems
by Claudia Pütz & Christian Hagist - 231-237 A decomposition of income-related health inequality applied to EQ-5D
by Jens Gundgaard & Jørgen Lauridsen - 238-246 Cost effectiveness of preventive home visits to the elderly
by Christian Kronborg & Mikkel Vass & Jørgen Lauridsen & Kirsten Avlund - 247-254 Cost-benefit analysis of a plant sterol containing low-fat margarine for cholesterol reduction
by A. Gerber & T. Evers & H. Haverkamp & K. Lauterbach - 255-264 Cost-effectiveness of the Danish smoking cessation interventions
by Kim Olsen & Lone Bilde & Henrik Juhl & Niels Kjaer & Holger Mosbech & Torben Evald & Mette Rasmussen & Helle Hiladakis - 265-269 The demand for private health care under national health insurance
by Y. Machnes - 270-275 Economic cost associated with type II diabetes in Spanish patients
by Miguel Ballesta & Florentino Carral & Gabriel Olveira & José Girón & Manuel Aguilar - 276-284 Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany
by Alan Brennan & Roberta Ara & Raimund Sterz & Bernd Matiba & Rito Bergemann - 285-289 Tests of stationarity and cointegration of health care expenditure and gross domestic product
by Halil Kiymaz & Yasemin Akbulut & Ahmet Demir - 290-296 Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany
by W. Greiner & K. Lehmann & S. Earnshaw & C. Bug & R. Sabatowski
September 2006, Volume 7, Issue 3
- 155-157 Risk-sharing agreements for innovative drugs
by Gérard Pouvourville - 158-164 Nonmedical economic consequences attributable to visual impairment
by Antoine Lafuma & Antoine Brezin & Francis Fagnani & Viviane Mimaud & Mounir Mesbah & Gilles Berdeaux - 165-172 A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany
by Stephen Beard & Fiona Maciver & Johannes Clouth & Eckart Rüther - 173-178 Test-retest reliability of willingness to pay
by Alan Shiell & Penelope Hawe - 179-184 The costs of schizophrenia in Spain
by Juan Oliva-Moreno & Julio López-Bastida & Rubén Osuna-Guerrero & Angel Montejo-González & Beatriz Duque-González - 185-191 Health care in the CIS countries
by Anatoly Pilyavsky & Matthias Staat - 192-194 Problems and costs associated with alcohol and drug abuse in emergency medicine
by F.-X. Huber & T. Hackert & P. Meeder - 195-203 Determinants of household health expenditure on western institutional health care
by Tin Su & Subhash Pokhrel & Adjima Gbangou & Steffen Flessa - 204-211 Price regulation and generic competition in the pharmaceutical market
by Dag Dalen & Steinar Strøm & Tonje Haabeth - 212-217 Alcohol-related mortality, drinking behavior, and business cycles
by Edvard Johansson & Petri Böckerman & Ritva Prättälä & Antti Uutela - 218-220 Decision models in the evaluation of psychotropic drugs
by Corrado Barbui & Camilla Lintas
July 2006, Volume 7, Issue 2
- 5-13 Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Bengt Jönsson - 14-23 Costs and quality of life of multiple sclerosis in Austria
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Carlotta Plesnilla & Ulf Baumhackl & Thomas Berger & Harald Kolleger & Karl Vass - 24-33 Costs and quality of life for patients with multiple sclerosis in Belgium
by Gisela Kobelt - 34-44 Costs and quality of life of multiple sclerosis in Germany
by Gisela Kobelt & Jenny Berg & Peter Lindgren & W. Elias & P. Flachenecker & M. Freidel & N. König & V. Limmroth & E. Straube - 45-54 Costs and quality of life of multiple sclerosis in Italy
by Gisela Kobelt & Jenny Berg & Peter Lindgren & M. Battaglia & C. Lucioni & A. Uccelli - 55-64 Costs and quality of life in multiple sclerosis in The Netherlands
by Gisela Kobelt & J. Berg & P. Lindgren - 65-74 Costs and quality of life of multiple sclerosis in Spain
by Gisela Kobelt & J. Berg & P. Lindgren & G. Izquierdo & O. Sánchez-Soliño & J. Pérez-Miranda & M. Casado - 75-85 Costs and quality of life of multiple sclerosis in Sweden
by Jenny Berg & P. Lindgren & Sten Fredrikson & Gisela Kobelt - 86-95 Costs and quality of life of multiple sclerosis in Switzerland
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Andrea Gerfin & J. Lutz - 96-104 Costs and quality of life of multiple sclerosis in the United Kingdom
by Gisela Kobelt & Jenny Berg & P. Lindgren & J. Kerrigan & N. Russell & R. Nixon
July 2006, Volume 7, Issue 02
- 5-13 Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Bengt Jönsson - 14-23 Costs and quality of life of multiple sclerosis in Austria
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Carlotta Plesnilla & Ulf Baumhackl & Thomas Berger & Harald Kolleger & Karl Vass - 24-33 Costs and quality of life for patients with multiple sclerosis in Belgium
by Gisela Kobelt - 34-44 Costs and quality of life of multiple sclerosis in Germany
by Gisela Kobelt & Jenny Berg & Peter Lindgren & W. Elias & P. Flachenecker & M. Freidel & N. König & V. Limmroth & E. Straube - 45-54 Costs and quality of life of multiple sclerosis in Italy
by Gisela Kobelt & Jenny Berg & Peter Lindgren & M. Battaglia & C. Lucioni & A. Uccelli - 55-64 Costs and quality of life in multiple sclerosis in The Netherlands
by Gisela Kobelt & J. Berg & P. Lindgren - 65-74 Costs and quality of life of multiple sclerosis in Spain
by Gisela Kobelt & J. Berg & P. Lindgren & G. Izquierdo & O. Sánchez-Soliño & J. Pérez-Miranda & M. Casado - 75-85 Costs and quality of life of multiple sclerosis in Sweden
by Jenny Berg & P. Lindgren & Sten Fredrikson & Gisela Kobelt - 86-95 Costs and quality of life of multiple sclerosis in Switzerland
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Andrea Gerfin & J. Lutz - 96-104 Costs and quality of life of multiple sclerosis in the United Kingdom
by Gisela Kobelt & Jenny Berg & P. Lindgren & J. Kerrigan & N. Russell & R. Nixon
June 2006, Volume 7, Issue 2
- 89-90 Pharmaceutical policy in Italy
by Livio Garattini & Dante Cornago - 91-98 The reasons of general practitioners for promoting colorectal cancer mass screening in France
by Célia Berchi & Jean-Marc Dupuis & Guy Launoy - 99-106 Choices and utilization in dental care
by Lien Nguyen & Unto Häkkinen - 107-113 Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer
by Samuel Limat & Claire-Hélène Bracco-Nolin & Christine Legat-Fagnoni & Loic Chaigneau & Ulrich Stein & Bernard Huchet & Xavier Pivot & Marie-Christine Woronoff-Lemsi - 114-116 Health care and patients’ migration across Spanish regions
by David Cantarero - 117-122 The future of imaging techniques for cancer patients in The Netherlands
by Theo Postma & Janneke Alers & Sijmon Terpstra & Arjan Zuurbier - 123-128 Factors influencing the costs of emergency medical admissions to an Irish teaching hospital
by Edward Moloney & Kathleen Bennett & Bernard Silke - 129-136 Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers
by Hans-Georg Eichler & Sheldon Kong & Jean-Pierre Grégoire - 137-144 Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain
by Fernando Antonanzas & Benoit Rive & Josep Badenas & Susana Gomez-Lus & Chantal Guilhaume - 145-146 Costs of chemotherapy in the treatment of colorectal cancer
by F. Jansman & M. Postma - 147-151 A taxonomy of health utility assessment methods and the role for uncertainty analysis
by Agota Szende & Caroline Schaefer
March 2006, Volume 7, Issue 1
- 5-6 The desirability and feasibility of economic studies of drugs post-launch
by Michael Drummond & Anne Mason & Adrian Towse - 7-18 The relationship between health care expenditure and health outcomes
by John Nixon & Philippe Ulmann - 19-29 Pharmacoeconomic modelling in schizophrenia
by Karina Hansen & Christophe Lançon & Mondher Toumi - 30-36 Comparing costs and effectiveness of different starting points for highly active antiretroviral therapy in HIV-positive patients
by Monica Merito & Patrizio Pezzotti - 37-45 Fixed budgets as a cost containment measure for pharmaceuticals
by David Granlund & Niklas Rudholm & Magnus Wikström - 46-54 The Danish effect on Swedish alcohol costs
by Johan Jarl & Ulf-G. Gerdtham & Carl Lyttkens & Thor Lithman & Juan Merlo - 55-65 Prospective casemix-based funding, analysis and financial impact of cost outliers in all-patient refined diagnosis related groups in three Belgian general hospitals
by Magali Pirson & Dimitri Martins & Terri Jackson & Michèle Dramaix & Pol Leclercq - 66-71 Case-control analysis of the financial cost of medication errors in hospitalized patients
by Jaime Pinilla & Carles Murillo & Genís Carrasco & Carlos Humet - 72-78 Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care
by Steven Edwards & Helen Campbell & Jonathan Plumb - 79-83 Off-patent drugs in Italy
by Livio Garattini & Simone Ghislandi
December 2005, Volume 6, Issue 4
- 285-287 How much are health-care systems prepared to pay to produce a QALY?
by Martin Buxton - 288-297 Trial-based cost-utility comparison of percutaneous myocardial laser revascularisation and continued medical therapy for treatment of refractory angina pectoris
by Helen Campbell & Sue Tait & Linda Sharples & Noreen Caine & Timothy Gray & Peter Schofield & Martin Buxton - 298-308 Does testing for prostate-specific antigen contribute to declining prostate cancer mortality?
by L. Di Matteo & R. Di Matteo - 309-313 Indirect costs of cervical and breast cancers in Spain
by Juan Oliva & Félix Lobo & Julio López-Bastida & Néboa Zozaya & Rosa Romay - 314-316 Discrete choice experiments in health economics: Distinguishing between the method and its application
by Emily Lancsar & Cam Donaldson - 317-321 Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany
by Werner Kulp & J.-M. Schulenburg & Wolfgang Greiner - 322-333 Hospital development plans
by Steffen Fleßa - 334-346 Can economic evaluations be made more transferable?
by Stephanie Boulenger & John Nixon & Michael Drummond & Philippe Ulmann & Stephen Rice & Gerard Pouvourville - 347-353 Estimating utility data from clinical indicators for patients with stable angina
by Louise Longworth & Martin Buxton & Mark Sculpher & David Smith - 354-362 The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention
by Anna Ringborg & Peter Lindgren & Bengt Jönsson
September 2005, Volume 6, Issue 3
- 191-196 Health economic evaluation of disease management programs
by Wolfgang Greiner - 197-202 The economic and quality of life impact of hypoglycemia
by Jonas Lundkvist & Christian Berne & Björn Bolinder & Linus Jönsson - 203-214 Use of a decision analysis model to assess the medicoeconomic implications of FDG PET imaging in diagnosing a solitary pulmonary nodule
by Catherine Lejeune & Kazem Al Zahouri & Marie-Christine Woronoff-Lemsi & Patrick Arveux & Alain Bernard & Christine Binquet & Francis Guillemin - 215-222 Institutional arrangements and efficiency of health care delivery systems
by Vasanthakumar Bhat - 223-232 A cross-national perspective on cost of illness
by Johan Polder & Willem Meerding & Luc Bonneux & Paul Maas - 233-243 An empirical analysis of tobacco addiction in Italy
by Silvia Tiezzi - 244-252 Influenza treatment with neuraminidase inhibitors
by Beate Sander & Marlene Gyldmark & Frederick Hayden & James Morris & Elvira Mueller & Rito Bergemann - 253-260 Measuring health-related utility:
by Stirling Bryan & Louise Longworth - 261-266 Comparison of general practitioner records and patient self-report questionnaires for estimation of costs
by Hema Mistry & Martin Buxton & Louise Longworth & Judy Chatwin & Robert Peveler - 267-273 The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland
by Lesley Tilson & Kathleen Bennett & Michael Barry - 274-279 Reimbursement and clinical guidance for pharmaceuticals in Sweden
by Anders Anell & Ulf Persson
June 2005, Volume 6, Issue 2
- 91-93 Practice guidelines based on clinical and economic evidence
by Frans Rutten & Werner Brouwer & Louis Niessen - 94-101 Costs of hospitalization for severe acute asthma of patients not treated according to guidelines and recommendations
by Jean-Claude Sailly & Xavier Lenne & Caroline Bercez & Thérèse Lebrun & Antoine-Bernard Tonnel & Isabelle Tillie-Leblond - 102-106 Cost of home palliative care compared with conventional hospital care for patients with haematological cancers in Greece
by Sofia Tzala & Joanne Lord & Nikolaos Ziras & Panayotis Repousis & Anna Potamianou & Evangelia Tzala - 107-111 Time preference bias in time trade-off
by Marjon Pol & Larissa Roux - 112-123 Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany
by Uwe Siebert & Gaby Sroczynski & Jürgen Wasem & Wolfgang Greiner & Ulrike Ravens-Sieberer & Pamela Aidelsburger & Bärbel Kurth & Monika Bullinger & J.-Matthias Schulenburg & John Wong & Siegbert Rossol - 124-130 Validating the EQ-5D with time trade off for the German population
by W. Greiner & C. Claes & J. J. V. Busschbach & J.-M. Schulenburg - 131-135 Spatial competition for quality in the market for hospital care
by Marcello Montefiori - 136-145 Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom
by J. Guest & J. Russ & A. Lenox-Smith - 146-151 Order bias in estimates of willingness to pay for drugs to treat attention-deficit/hyperactivity disorder
by Annemieke De Ridder & Diana De Graeve - 152-158 Risk and potential risk reduction in diabetes type 2 patients in Germany
by Bertram Häussler & Ursula Berger & Oliver Mast & Wolfgang Thefeld - 159-165 Economic burden of hepatitis C in Canada and the potential impact of prevention
by Susie El Saadany & Douglas Coyle & Antonio Giulivi & Mohammad Afzal - 166-171 The direct medical cost of diabetes in Israel
by Gabriel Chodick & Anthony Heymann & Francis Wood & Ehud Kokia - 172-182 The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation
by Christophe Legendre & Stephen Beard & Anne Crochard & Yvon Lebranchu & Claire Pouteil-Noble & Anke Richter & Isabelle Durand-Zaleski - 183-187 German health care system in transition
by J.-Matthias Schulenburg
March 2005, Volume 6, Issue 1
- 2-7 Criteria for determining a basic health services package
by E. Stolk & M. Poley - 8-15 Consumer preferences in social health insurance
by Jan Kerssens & Peter Groenewegen - 16-23 Modeling the economic burden of diseases imputable to stress at work
by Sophie Béjean & Hélène Sultan-Taïeb - 30-37 The cost-effectiveness of human papillomavirus screening for cervical cancer
by Jeremy Holmes & Lindsay Hemmett & Susan Garfield - 38-44 Collecting unit cost data in multicentre studies
by Sarah Wordsworth & Anne Ludbrook & Fergus Caskey & Alison Macleod - 45-52 Bayesian regression models for cost-effectiveness analysis
by Francisco-José Polo & Miguel Negrín & Xavier Badía & Montse Roset - 53-64 Substance abuse treatment, what do we know?
by Matilde Machado - 65-72 A modified three-stage data envelopment analysis
by Jos Blank & Vivian Valdmanis - 73-82 A ‘new and improved’ EQ-5D valuation questionnaire?
by Nancy Devlin & Paul Hansen & Peter Herbison & Susan Macran - 83-86 On the (mis)use of cross-price effects to gauge the effectiveness of smokeless tobacco in smoking cessation
by Richard Ault & T. Beard & John Jackson & Richard Saba
November 2005, Volume 6, Issue 1
- 2-10 Defining the “Health Benefit Basket” in nine European countries
by J. Schreyögg & T. Stargardt & M. Velasco-Garrido & R. Busse - 11-17 The “Health Benefit Basket” in Denmark
by Lone Bilde & Anni Ankjaer-Jensen & Bent Danneskiold-Samsøe - 18-23 Does the English NHS have a ‘Health Benefit Basket’?
by Anne Mason - 24-29 The “Health Benefit Basket” in France
by Martine Bellanger & Veneta Cherilova & Valérie Paris - 30-36 Determining the “Health Benefit Basket” of the Statutory Health Insurance scheme in Germany
by Reinhard Busse & Tom Stargardt & Jonas Schreyögg